Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

The efficacy and safety of sumatriptan intranasal powder in adults with acute migraine. Expert Rev Neurother 2016 07;16(7):743-7 PMID: 27260875

Pubmed ID

27260875

DOI

10.1080/14737175.2016.1195687

Abstract

There are multiple choices of agents for the acute management of migraine available. Patient-specific factors such as associated symptoms including nausea, vomiting, and gastroparesis are important considerations. Oral administration may often be the patient-preferred route of delivery because of comfort or convenience but when it is important to bypass gut absorption then either parenteral or intranasal administration may be appropriate delivery approaches. A new formulation of a low-dose sumatriptan intranasal powder administered via a novel breath-powered delivery device may be a viable option Areas covered: Our search of the available literature pertaining to the topic of intranasal sumatriptan powder yielded pharmacokinetic studies and randomized, double-blind, placebo-controlled trials (including The TARGET Study, The COMPASS study) published between 2010 and 2015. Expert commentary: A new formulation of a low-dose sumatriptan intranasal powder administered via a novel breath-powered delivery device appears to be a safe and efficacious option for the acute management of a migraine ideally suited for this situation. It appears to have superior efficacy to sumatriptan 100 mg oral tablets with superior pain freedom by 15 minutes and pain relief over the initial 30 minutes post-dose.

Author List

Freitag FG, Shumate DA

Author

Frederick G. Freitag DO Associate Professor in the Neurology department at Medical College of Wisconsin




Scopus

2-s2.0-84976430938

MESH terms used to index this publication - Major topics in bold

Administration, Intranasal
Adult
Humans
Migraine Disorders
Powders
Serotonin Receptor Agonists
Sumatriptan
jenkins-FCD Prod-331 a335b1a6d1e9c32173c9534e6f6ff51494143916